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ABSTRACT
Introduction. Posttreatment surveillance protocols most
often endure for 5 years after resection of colorectal liver
metastasis (CRLM). Most recurrences happen within
3 years after surgical removal of the tumour. This study
analysed the need of surveillance for patients with at least
3 years of disease-free survival after potentially curative
resection of CRLM.
Methods. A single-centre, retrospective analysis of all
consecutive patients who underwent treatment for CRLM
with curative intent between 2000 and 2011.
Results. In total, 152 of 545 patients (28 %) remained
disease-free for 3 years after successful resection of the
CRLM. The estimated recurrence rate after 10 years of
follow-up in this group of 152 patients was 27 %. More
than half of these patients (55 %) could be treated with
curative intent for their recurrences. Multivariable analysis
revealed that the nodal status of the primary tumour is of
significant prognostic value for developing recurrences
after 3 years of disease-free survival. A disease-free
interval of less than 12 months between resection of pri-
mary tumour and detection of CRLM shows a trend
towards significance. Both factors were used to create a
risk score, showing that patients with a low-risk profile
(node-negative status and a disease-free inter-
val\12 months) have an estimated recurrence rate of 5 %
and might not benefit from intensive surveillance beyond
3 years of follow-up without a recurrence.
Conclusions. The currently developed risk score shows that
follow-up can be stopped in a specific subgroup 3 years after
treatment for their CRLM with curative intent.
Liver metastases are common in patients with colorectal
cancer (CRC), developing in approximately half of patients
with colorectal tumours.1,2 Surgical treatment of colorectal
liver metastasis (CRLM) results in 5-year overall survival
(OS) of 40–60 %.3,4 Although the treatment of CRLM has
improved, disease recurrence is seen in almost 70 % of the
patients. Most often recurrences develop during the first
3 years after surgery.5–7 Both hepatic and pulmonary
recurrences can be treated with local therapy repeatedly,
thereby still offering the potential of cure.8–13 The oppor-
tunity to control recurrent disease as a curable condition
increased interest in the surveillance of patients after
hepatectomy. No consensus on the optimal follow-up
protocol for curatively treated patients with stage IV CRC
has been reached however.
Patients treated with curative intent for CRLM enter a
surveillance scheme, enduring for 5 years in most centres.
Research on the surveillance and prognosis of patients with
CRLM mainly focuses on the first 3 years after surgery,
because most recurrences happen during this period. Lit-
erature is scarce on the follow-up of patients with a
disease-free survival (DFS) of 3 years and more.14 The
current study was designed to analyse the need for
surveillance in these patients by determining the recurrence
pattern, treatment for recurrences, and oncological out-
come. This study assessed the possibilities for a risk-based
surveillance protocol in this highly selected but growing
group of patients.
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PATIENTS AND METHODS
Patient data were extracted from a prospectively main-
tained database in Erasmus MC Cancer Institute. The
database consists of perioperative and clinicopathological
characteristics of primary CRC, CRLM, and recurrent
metastatic disease. In this retrospective analysis, patients
who received surgical or ablative therapy for CRLM
between January 2000 and November 2011 were included.
In this group, all patients with a DFS of more than 3 years
were identified. In case of relapsing disease after liver
surgery, data on recurrence location, diagnosis, and treat-
ment were collected.
Follow-Up of Patients with CRLM
Surveillance consisted of physical examination, thora-
coabdominal computed tomography (CT) and regular
serum carcinoembryonic antigen (CEA) level measure-
ments. Patient surveillance was performed for up to 5 years
after treatment of CRLM. During this period, serum CEA
measurements and radiological imaging were performed
every 3–6 months during the first 3 years after surgery and
yearly thereafter.
Recurrent Disease
In the present study, recurrences detected within 3 years
of CRLM treatment with curative intent were categorized
as early recurrences. All recurrences detected after 3 years
were considered to be late recurrences. CEA blood
levels[5.00 lg/L were considered elevated. In case of
normal CEA levels, the absolute difference between
baseline postoperative CEA levels and CEA levels at time
of recurrence was calculated.
Treatment of recurrent disease was assessed in a multi-
disciplinary tumour board for all patients. Because long-term
local control of metastatic CRC is achieved using surgery,
radiofrequency ablation (RFA), or stereotactic radiotherapy
(SRx), all of these modalities were considered to be poten-
tially curative treatments for recurrent disease.15,16
Disease-Free and Overall Survival
Disease-free survival was calculated as the time in
months between the resection of CRLM and the diagnosis
of recurrent disease (either by radiology, physical exami-
nation, or endoscopy). When an elevated CEA level was
the first sign of possible recurrence, this was followed by
confirmative imaging or biopsies. The dates of the latter
were used for survival calculations.
Overall survival was the time between treatment of
CRLM and the date of death or last follow-up. For both
patients with a DFS of 3 and 5 years, conditional OS and
DFS curves were created, using 36 and 60 months as the
starting points (t0). To compare oncological outcome after
potentially curative treatment for early and late recur-
rences, the survival estimate DFS2 (from start treatment of
recurrence until re-recurrence) was calculated.
Statistical Analysis
The categorical data are presented as absolute numbers
and percentages. Continuous variables were displayed as
means (and standard deviations) or medians (and
interquartile ranges). Different proportions between groups
were tested using the Chi squared test. Univariable and
multivariable regression models were created to identify
factors related to late disease recurrence, for which hazard
ratios (HR) and 95 % confidence intervals (CI) were calcu-
lated. Prognostic factors were used to create a risk score. The
score was internally validated for discrimination (concor-
dance index) and calibration (calibration plot), using
bootstrap resampling. The Kaplan–Meier method was used
to estimate (conditional) survival. All (conditional) survival
estimates were compared using the log-rank test. A p
value\0.05 was considered significant. All analyses were
performed using SPSS version 21.0 (SPSS Inc., Chicago, IL)
and R version 3.2.5 (http://www.r-project.org).
RESULTS
Of the 607 patients with a minimal potential follow-up
of 3 years and potentially curative treatment for CRLM,
545 consecutive patients (90 %) were eligible for analysis
in this study. Exclusion criteria are presented in Fig. 1. A
total of 152 patients were disease-free after 3 years of
follow-up (28 %), of which 31 patients (20 %) developed
recurrences beyond 3 years. Median follow-up time
(t0 = 36 months after first hepatectomy) was 40 months
(interquartile range: 18–63 months) in this group. Twenty-
four patients (16 %) died during the follow-up period. In
patients with 3 years of DFS, the Kaplan–Meier analysis
showed an estimated recurrence rate of 27 % in the fol-
lowing 7 years of follow-up.
Eighty-one patients were disease-free for more than
5 years (15 %). Median follow-up time in this group of
patients (t0 = 60 months after first hepatectomy) was
31 months (interquartile range: 20–52 months). Seven
recurrences (9 %) and six deaths (7 %) were observed, and
the estimated (Kaplan–Meier) probabilities of recurrence
and mortality in the following 5 years were 11 and 12 %
respectively. Conditional OS and DFS curves are presented
in Fig. 2 for patients with 3 and 5 years of DFS. In total,
393 patients (72 %) had a DFS of less than 3 years. When
comparing the recurrence pattern of early (\3 years DFS)
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and late recurrences ([3 years DFS), no significant dif-
ferences in tumour location were seen (Table 1).
After evaluation of the late recurrences, 17 patients
(55 %) could be treated with curative treatment modalities
compared with 168 (45 %) of the early recurrences
(p = 0.293). For patients with curatively treated early
recurrences, re-recurrence occurred earlier than in patients
with curatively treated late recurrences. Median time to
relapse (DFS2) was 28 months (75th percentile at
12 months, 25th not reached) in patients with late recur-
rences and 8 months (interquartile range: 4–30 months) in
patients with early recurrences (p = 0.041). Table 1 dis-
plays treatment and surveillance results of early and late
recurrences.
To define patients who potentially could be excluded
from follow-up, the Chi squared test and univariable Cox
607 patients underwent
surgery for CRLM.
Reasons for exclusion (62 patients):
1. Progression of disease in staged treatment (33
     patients, 53%):
 -  13 liver first without resection primary 
    CRC (21%)
 -  12 progression in between 2-staged 
     liver resection (19%)
 -  7 untreated extra-hepatic disease 
    other than primary (11%)
 -   1 co-morbidity in between 2 staged 
      liver resection (2%)
2.  Unexpected findings during laparotomy (25 
      patients, 40%):
 -   14 peritonitis carcinomatosa (23%)
 -    8 irresectable CRLM (13%)
 -    3 distant lymph node intra-
                   operative (5%) 
3.  Lost to follow-up (4 patients, 6%).
545 patients entered the 
regular follow-up scheme
20 patients  (4%) died within 
three years before developing recurrent 
disease. 
525 patients (96%) with 
possible recurrence after 
metastasectomy of CRLM
373 patients (68%) 
< 3 years DFS
152 patients (28%)
> 3 years DFS
31 patients (20%)
with recurrence 
> 3 years DFS
121 patients (80%)
without recurrence
FIG. 1 Flowchart of the study
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regression analysis were performed. Factors associated
with developing late disease recurrences were the nodal
status of the primary tumour, the absence of neoadjuvant
chemotherapy for CRLM, and the disease-free interval
(DFI) between resection of the primary CRC and the
detection of CRLM. The Clinical Risk Score (CRS)
described by Fong et al. showed no additional value in
assessing the probability of developing late recurrence.17
After multivariable analysis, the nodal status remained
a statistically significant prognostic factor for late disease
recurrence after an initial DFS of 3 years. A DFI of more
than 12 months between resection primary and
TABLE 1 Recurrence pattern, surveillance and treatment results
Recurrence\3 years (N = 373) Recurrence[3 years (N = 31) p-value
Location recurrence
Intrahepatic only 144 (39 %) 9 (29 %) 0.291
Extrahepatic location recurrences 229 (61 %) 22 (71 %) 0.904
Pulmonary recurrence 84 (23 %) 11 (36 %)
Local recurrence 15 (4 %) 1 (3 %)
Distant lymph nodes 21 (6 %) 1 (3 %)
Hepatic and pulmonary 35 (9 %) 1 (3 %)
Hepatic and other 28 (8 %) 4 (13 %)
Pulmonary and other 15 (4 %) 2 (7 %)
Multi-organ metastasis (C3) 10 (3 %) 1 (3 %)
Other locations 21 (6 %) 1 (3 %)
Surveillance
Median CEA (IQR) lg/L 7.0 (2.9–20.0) 7.1 (3.9–12.7) 0.849
Elevated CEA ([5.0 lg/L) 204 (55 %) 22 (71 %) 0.087
Non elevated CEA (\5.0 lg/L) 152 (40 %) 8 (26 %)
Missing CEA values 17 (5 %) 1 (3 %)
Perc. increase (when normal CEA) 152 (40 %) 8 (26 %) 0.255
[25 % compared to baseline 49 (29 %) 4 (50 %)
1–25 % compared to baseline 25 (15 %) 2 (25 %)
Decreased compared to baseline 26 (16 %) 2 (25 %)
Not calculated 52 (34 %) 0 (0 %)
Treatment
Curative 168 (45 %) 17 (55 %) 0.293
Non-curative 205 (55 %) 14 (45 %)
FIG. 2 Conditional DFS and OS for patients with 3 and 5-years DFS
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TABLE 2 Baseline characteristics of patients with 3 years of DFS and the results of univariable and multivariable analysis
Variables Total (N = 152) Recurrence




[HR (95 % CI) p-value]
Multivariable
[HR (95 % CI) p-value]
Gender
Male 94 19 (20.2 %) 0.943 0.942 (0.456–1.943)
Female 58 12 (20.7 %) 0.871
Age
Median (range) 64 (30–86) 66 (30–86) 0.326 1.030 (0.994–1.067)
Mean ± SD 63.3 ± 11.1 65.9 ± 13.2 0.106
Primary CRC
Location
Colon 93 19 (20.4 %) 0.989 0.978 (0.475–2.015)
Rectum 59 12 (20.3 %) 0.952
T-stage
T3-4 37 3 (8.1 %) 0.086 3.250 (0.989–10.682)
Tl-2 114 28 (24.6 %) 0.052
Node status
Positive 72 20 (27.8 %) 0.035 2.316 (1.109–4.837) 2.279 (1.090–4.764)
Negative 79 11 (13.9 %) 0.025 0.029
Adjuvant CTx
Yes 31 9 (29.0 %) 0.181 1.890 (0.868–4.116)
No 121 22 (18.2 %) 0.109
CRLM
DFI\12 months
Yes 93 12 (12.9 %) 0.004 0.372 (0.180–0.766) 0.471 (0.215–1.029)
No 59 19 (32.2 %) 0.007 0.059
Number of CRLM
[1 75 14 (18.7 %) 0.602 1.002 (4.94–2.033)
1 77 17 (22.1 %) 0.996
Size of tumours
C5.00 cm 26 7 (26.9 %) 0.386 1.382 (0.595–3.210)
4.99 cm 124 24 (19.4 %) 0.451
CEA preoperative
C200 lg/L 8 1 (12.5 %) 0.305 0.045 (0.00–46.585)
B199 lg/L 120 22 (18.3 %) 0.381
Bilobar metastases
Yes 43 9 (20.9 %) 0.918 1.218 (0.560–2.647)
No 109 22 (20.2 %) 0.691
Neoadjuvant CTx
Yes 70 8 (11.4 %) 0.011 0.411 (0.184–0.920) 0.577 (0.241–1.380)
No 82 23 (28.0 %) 0.03 0.216
Margin\1 mm
Yes 22 4 (18.2 %) 0.743 0.985 (0.344–2.815)
No 127 27 (21.3 %) 0.977
EHD
Yes 3 0 (0.0 %) 0.376 0.048 (0.00–8158.217)
No 149 31 (20.8 %) 0.621
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development CRLM) shows a trend towards significance
(Table 2).
Risk categories for late recurrences were created, in
which patients with node-negative primary tumours and a
DFI of less than 12 months (n = 50, 33 %) were consid-
ered at low-risk. All other patients (with either a N? status,
a DFI of more than 12 months, or a combination of both
characteristics) were considered at high-risk of late recur-
rence (n = 101, 66 %). In one patient, no risk score could
be determined. In the low-risk group, two patients (4 %)
developed recurrence during the following 2 years of
surveillance (after the initial 3 disease-free years) com-
pared with 22 patients (22 %) in the high-risk group. The
estimated 10-year recurrence rate in the low-risk group was
5 % and was 25 % in the high-risk group (p = 0.005). The
sensitivity of this risk score for prediction of late recur-
rences during the last 2 years of follow-up was 92 %. The
estimated difference in recurrence rate between the ‘‘high-
risk’’ group and the complete group of patients with
3 years of DFS is 2 %. This means that 50 patients with a
DFS of 3 years need to remain in follow-up for another
2 years to detect 1 ‘‘low-risk’’ patient with late recurrent
disease.
After 5 years of DFS, one recurrence (3 %) was
observed in the low-risk group (n = 32) compared with six
recurrences (12 %) in the high-risk group (n = 49). The
estimated 10-year recurrence rate in the following 5 years
(after 5 years of DFS) was 3 % in the low-risk group
versus 15 % in the high-risk group (p = 0.207). Kaplan–
Meier curves after 3 and 5 years of DFS are presented in
Fig. 3.
The created risk model had a moderate capacity to
predict late disease recurrence (bootstrap corrected con-
cordance index: 0.71) and acceptable calibration (see
Supplementary Material).
DISCUSSION
The current study demonstrates that a considerable
proportion of patients with a DFS of more than 3 years
develop recurrences, with an estimated 10-year recurrence
rate of 27 %. Patients with late recurrences received
potentially curative treatment as often as patients with early
recurrences did. This may justify surveillance in patients
with CRLM, even after a DFS of 3 years.
To date, no prospective trials have investigated the
efficacy of long-term follow-up of patients with CRLM,
nor curatively treated stage IV CRC in general. It is still
unclear to what extend surveillance is useful. The primary
target of this study was to objectify the necessity of
TABLE 2 continued
Variables Total (N = 152) Recurrence




[HR (95 % CI) p-value]
Multivariable
[HR (95 % CI) p-value]
Clinical risk score
HR (3–5) 39 7 (17.9 %) 0.550 0.809 (0.347–1.886)
LR (0–2) 102 23 (22.5 %) 0.624
Missing values were observed for T-stage (1), nodal status (1), tumour size (2), preoperative CEA (24), margin status (3 patients with RFA only)
and the Clinical Risk Score (11)
CTx chemotherapy, EHD extra-hepatic disease, CEA carcinoembryonic antigen, LR low-risk, HR high-risk
FIG. 3 Risk stratification for late recurrences. The graph on the left illustrates the DFS during the last 2 years of follow-up (from 36 to
60 months after hepatectomy). The graph on the right illustrates the DFS after more than 60 months after hepatectomy
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surveillance in patients without evidence of disease 3 years
after the first liver metastasectomy. Several groups have
shown that repeat resections of recurrences offer survival
benefit and although the efficacy of RFA and SRx has been
studied less intensively, results indicate that long-term
disease control can be reached using these treat-
ments.15,16,18–22 Because more than half of the patients
with late recurrences were treated with either one or a
combination of local treatments, surveillance seems legit-
imate in this particular group of patients.
Follow-up in the centre of the current study is performed
during 5 years for all patients after resection of CRLM,
which is advised in the ASCRS and NCCN guidelines.23,24
Preferably cancer surveillance should only be performed in
those patients benefiting from it. In order to decide in
which patients follow-up is desirable, accurate prediction
of outcome after metastasectomy is needed. Many efforts
to determine prognosis of patients with CRLM have been
made, of which the CRS is mostly practised.4,17,25 Less
evidence is available to predict the likelihood of late dis-
ease recurrence, which is demonstrated by the fact that
patients with initially poor prognostic factors can still be
cured from CRLM.28 A study by Tan et al. showed that the
currently used risk scores for CRLM have little predictive
value in 3-year survivors of CRLM with regards to the
disease-specific survival and therefore are not suitable to
decide whether long-term follow-up is appropriate.29 In the
current study, the nodal status of the primary CRC showed
to be the only significant prognostic factor with respect to
developing late disease recurrence. The DFI was non-
significant in multivariable analysis but showed a trend
towards significance. The interval between resection of the
primary tumour and occurrence of CRLM has been used in
most CRS, as a DFI of less than a year increases the chance
of developing recurrent disease shortly after hepatec-
tomy.4,17,25–27 The results in this study indicate an opposite
effect in patients with 3 years of DFS, as patients with a
short interval (\12 months) between the primary CRC and
the occurrence of CRLM had a favourable outcome in this
particular group of patients. Although counterintuitive, this
finding might not be illogical. In many studies, a short DFI
is described as a risk factor for early recurrence and a
surrogate for aggressive tumour behaviour, inherently.17
Moreover, this means that if patients with a short DFI
develop recurrences, it is more likely that these will occur
in the period shortly after partial hepatectomy rather than
after a period of 3 years. This study showed that in the
period thereafter, patients with a short DFI had a lower risk
of developing recurrence, because it is unlikely that
patients with initially aggressive tumour behaviour will
develop recurrences after remaining disease-free for such a
significant period of time. Consequently, patients with a
prolonged DFI have a decreased risk in the period shortly
after surgery but remain at higher risk of recurrence for an
expanded period. Considering the more latent tumour
behaviour in patients with a prolonged DFI, this might not
be implausible. Although patient selection, rather than
tumour biology, also could explain the observed effect, this
finding might be of interest when considering long-term
surveillance in patients with CRLM and therefore should
be validated in an external cohort of patients.
To identify patients who could potentially be discharged
from (intensive) surveillance, a stratification system was
created using both the DFI and nodal status as variables.
Patients with optimal prognostic factors (pN0 status and a
DFI\12 months) were considered to be at low-risk,
resulting in an estimated recurrence probability of 5 %.
The results display that this is lower than the estimated
12 % recurrence probability after 5 years of DFS, when it
is generally accepted to discharge patients from follow-up.
The risk score showed moderately good discrimination and
acceptable calibration. Although this scoring system needs
external validation and potentially could be extended with
other variables, this study indicates that there may be
patients with a low-risk profile who do not benefit from a
surveillance protocol consisting of 5 years and can either
be discharged from follow-up after 3 years or undergo less
intensive surveillance by the general practitioner.
During the past decade, several research groups have
retrospectively evaluated the different aspects of follow-up
after metastasectomy to define an optimal surveillance
protocol.30–37 Jones et al. highlighted the lack of evidence
surrounding surveillance of patients with CRLM after
reviewing all available literature on early intensive follow-
up after metastasectomy and therefore remained incon-
clusive on how to perform optimal follow-up.14 In a review
by Metcalfe et al. 5 years of follow-up was proposed.38 As
shown in this and other studies, patients with a DFS of
5 years still have a probability of approximately 10 % to
develop recurrences after being discharged from surveil-
lance. Recent literature stated that cure after resection of
CRLM might only be achieved after 10-year survival.28,39
This suggests that an extended follow-up protocol of more
than 5 years could be worthwhile for some patients, again
addressing the need for tailor-made follow-up schedules.
The current study has several limitations and its con-
clusions should be interpreted with care. As a result of the
retrospective nature of this study, the obtained results
might be biased. Due to the limited number of events after
3 years of DFS, only three factors could be evaluated in the
multivariable analysis. It is likely that other factors are
influential, although nonsignificant in this particular uni-
variable analysis. Also, the identified risk score has not
been externally validated, which impairs generalizability.
Nevertheless, this study provides valuable insights
regarding the follow-up of patients with 3 years of DFS
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after surgery for CRLM. The data suggest that follow-up in
patients surviving 3 years without evidence of disease is
useful and necessary in most patients. Patients with the
currently developed low-risk profile might not benefit from
the additional 2 years of surveillance, and patients with a
high-risk profile should be followed beyond 5 years, which
emphasizes the importance of a tailor-made, long-term,
follow-up protocol after treatment of CRLM with curative
intent.
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